Is Thymosin Alpha-1 Legal in Wisconsin?
HealthRX.com
No clear legal route to a Wisconsin pharmacy for thymosin alpha-1
Key numbers
- 1.6 mgItalian Zadaxin label dose per injection; no US-approved dose existsSource: fda.gov, as cited Nov 7, 2026
- 1056 peopleHepatitis B trials: 5 trials with 1056 people found low-certainty evidence of fewer serious adverse eventsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 4 yes and 17 noFDA advisory committee vote on adding thymosin alpha-1 to the compounding bulks list, December 2024Source: fda.gov, as cited Nov 7, 2026
- 17 million dosesZadaxin doses given after marketing, as reported by authors tied to the makerSource: fda.gov, as cited Nov 7, 2026
At a glance
- FDA approval / None. No US marketing application exists for thymosin alpha-1 [1]
- FDA list for state-licensed pharmacies / Not on it, and in none of the three nomination categories [2]
- FDA list for outsourcing facilities / Category 3, 'nominated without adequate support' [4]
- FDA advisory committee / Voted 4 yes, 17 no on both the free base and the acetate, December 2024 [5]
- October 2026 HHS peptide policy / Does not include thymosin alpha-1 [6]
- WADA Prohibited List / Not named on the 2026 List [7]
- Wisconsin law / Chapter 450 governs pharmacy licensure and does not name the peptide [3]
- Approved outside the US / Italy, India and Hong Kong, per FDA; Zadaxin is the brand [1]
Is thymosin alpha-1 legal in Wisconsin?
The federal status does most of the work here. A Drugs@FDA search found no US application for thymosin alpha-1; FDA's December 2024 review notes four US orphan drug designations, which are a separate process from approval and not an approval [1]. The peptide is a 28-amino-acid immune modulator that augments T-cell function, sold outside the US as Zadaxin 1.6 mg injections [1].
On the Wisconsin side, Wis. Stat. ch. 450 sets out pharmacy licensure, including licensure for out-of-state pharmacies [3]. The chapter does not name thymosin alpha-1.
Can a Wisconsin pharmacy compound it?
For state-licensed pharmacies and physicians, thymosin alpha-1 appears in none of the three categories on FDA's interim policy list (updated May 14, 2026), and the category 1 policy of generally no action against compounders does not apply to it [2]. The peptide had been in category 2, the significant-safety-risk group, and moved to the 'nominated but withdrawn' table after the nominators withdrew [8]. FDA's stated concerns remain: significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information the agency called 'inadequate ... to sufficiently understand the extent of any safety issues' [8].
On the separate list for outsourcing facilities, thymosin alpha-1 sits in category 3, 'nominated without adequate support' (list updated March 21, 2025) [4].
Questions worth asking
What FDA's advisers concluded
FDA proposed that thymosin alpha-1 not be added to the list of bulk substances that may be used in compounding. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate [5]. Members who voted no cited no compelling evidence of clinical effectiveness and safety; some who voted yes said patients should have access [5].
Thymosin alpha-1 is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy (BPC-157, epitalon, KPV, MOTS-c, Semax, TB-500) [6]. No FDA or HHS action allowing compounding of thymosin alpha-1 has been identified.
Is it approved anywhere else, or banned in sport?
FDA lists national authorizations in Italy (Zadaxin as an adjuvant to influenza vaccination in immunocompromised people), India (chronic hepatitis B in adults 18 and older with compensated liver disease and viral replication) and Hong Kong; a 2014 company annual report claims approvals across parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, which FDA could not independently verify [1]. Two reviews by authors tied to the Zadaxin developer say 'over 35 countries' (2009) and 'more than 30 countries' (2007) [9][10]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, not a marketing approval [1].
WADA does not name thymosin alpha-1 on its 2026 Prohibited List [7]. WADA does name thymosin-beta-4 and derivatives such as TB-500 in S2.3, a different peptide [7].
What is known about dose and safety
There is no US-approved dose. The Italian Zadaxin label gives 1.6 mg subcutaneously or intramuscularly twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination; it states not for children, contraindicated in pregnancy and breastfeeding, and advises caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].
Safety data are thin and partly company-linked. FDA's search of its adverse-event database in April 2024 found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report more than 4,400 trial participants and over 17 million doses of Zadaxin given after marketing, with adverse experiences 'infrequent and mild' [1]. A 2026 Cochrane review of hepatitis B trials found thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1056 people; low-certainty evidence) and fewer non-serious events (RR 0.47, 95% CI 0.27 to 0.83; very low certainty) [11]. The same review rated the evidence for benefit as very low certainty, and the reviewers said they were 'not sure' it helps [11].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in Wisconsin?
Can a Wisconsin pharmacy fill a thymosin alpha-1 prescription?
What did FDA's advisory committee decide about thymosin alpha-1?
Is thymosin alpha-1 approved in any country?
Is thymosin alpha-1 banned in sport?
Is thymosin alpha-1 safe?
References
Show all 11 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Wisconsin Legislature: Chapter 450.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.